Replies to post #200847 on Cytodyn Inc (CYDY)

[HyGro]

In NASH, just being better than placebo is the minimum. The leading NASH candidates were double the fat reduction of LL 350 mg. You saw the share price didn't rise at all. It is unlikely that 700 mg would double the 355 results, but it must to be even competitive -- but that is certainly not "breakthrough." The company is also hiding their fibrosis reduction results -- why?? That is a critical histological metric required to be competitive and get approved. The 350 mg was a mediocre first step and not a promising beginning.